July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Preservative-free versus preserved monotherapy: an in vivo confocal, prospective, masked, 36 months study on glaucoma patients
Author Affiliations & Notes
  • Gemma caterina Rossi
    Eye Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
  • Chiara Lumini
    Eye Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
  • Alessandra m Mirabile
    Eye Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
  • Erica Picasso
    Eye Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
  • Federica Bettio
    Eye Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
  • Alessia Paviglianiti
    Eye Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
  • Gian Maria Pasinetti
    beato palazzolo insitute, Bergamo, Italy
  • Footnotes
    Commercial Relationships   Gemma Rossi, None; Chiara Lumini, None; Alessandra Mirabile, None; Erica Picasso, None; Federica Bettio, None; Alessia Paviglianiti, None; Gian Maria Pasinetti, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3802. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gemma caterina Rossi, Chiara Lumini, Alessandra m Mirabile, Erica Picasso, Federica Bettio, Alessia Paviglianiti, Gian Maria Pasinetti; Preservative-free versus preserved monotherapy: an in vivo confocal, prospective, masked, 36 months study on glaucoma patients. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3802.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose :
To evaluate the in vivo effects of preservative-free (PF)-tafluprost versus other preserved prostaglandins on corneal health after 3 years of follow-up

Methods :
Prospective, masked, study on consecutive patients with a new prescription of PF-tafluprost (naïve-N or switched-S, 44 and 14 patients), and preserved bimatoprost 0.003% or travoprost 0.004% (P-group, 35 patients). A complete ophthalmic examination and an in vivo corneal confocal microscopy evaluation were performed at baseline and every 6 months for 3 years.

Results :
Clinical parameters were similar in the groups at baseline, apart from IOP, lower in the S-group (p=0.012). Both at baseline and over time, confocal microscopy parameters had different trends. At baseline, keratocyte activation was similar in the three groups (p=0.43) but over next months naïve patients treated with PF-tafluprost presented a significant (p=0.004) reduction in keratocyte activation. Sub-basal nerves tended to increase in patients switched to PF-tafluprost (p=0.07) while were stable in the other two groups (p=0.11 in PF and 0.40 in P group). Grade of tortuosity was stable over the time in the three groups. Beading-like formations were stable over the time for P- and PF-group, while significantly increased in S-group (p=0.027). Endothelial density values were statistically different at baseline (p=.007), they decreased both in PF-group and in S-group (p=0.048 and 0.001, respectively), while increased in P-group (p=0.006).

Conclusions :
Our study is the first to show that, after 36 months of topical daily therapy, a PF-tafluprost formulation does not significantly alter the corneal structures in naïve patients while improving corneal alterations due to chronic preserved therapies in patients switched to this therapy, as examined by confocal microscopy.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×